A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Huntington Disease
In brief
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Key facts
- Study ID
- NCT06826612
- Run by
- Hoffmann-La Roche
- People needed
- 53
- Starts
- 2025-02-21
- Expected to finish
- 2035-01-12
- Last updated by the study team
- 2026-05-05
Who can join
Age: 25 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- University of Cincinnati/Cincinnati Children's Hospital — Cincinnati, Ohio, United States (enrolling)
- Ohio State University — Columbus, Ohio, United States (enrolling)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- University of Pittsburg — Pittsburgh, Pennsylvania, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.